» Articles » PMID: 34680323

Intra-Tumour Genetic Heterogeneity and Prognosis in High-Risk Neuroblastoma

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2021 Oct 23
PMID 34680323
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Spatial ITH is defined by genomic and biological variations within a tumour acquired by tumour cell evolution under diverse microenvironments, and its role in NB patient prognosis is understudied. In this work, we applied pangenomic techniques to detect chromosomal aberrations in at least two different areas of each tumour and/or in simultaneously obtained solid and liquid biopsies, detecting ITH in the genomic profile of almost 40% of HR-NB. ITH was better detected when comparing one or more tumour pieces and liquid biopsy (50%) than between different tumour pieces (21%). Interestingly, we found that patients with ITH analysed by pangenomic techniques had a significantly better survival rate that those with non-heterogeneous tumours, especially in cases without amplification. Moreover, all patients in the studied cohort with high ITH (defined as 50% or more genomic aberration differences between areas of a tumour or simultaneously obtained samples) survived after 48 months. These results clearly support analysing at least two solid tumour areas (separately or mixed) and liquid samples to provide more accurate genomic diagnosis, prognosis and therapy options in HR-NB.

Citing Articles

Multicellular model of neuroblastoma proposes unconventional therapy based on multiple roles of p53.

Wertheim K, Chisholm R, Richmond P, Walker D PLoS Comput Biol. 2024; 20(12):e1012648.

PMID: 39715281 PMC: 11723635. DOI: 10.1371/journal.pcbi.1012648.


Unveiling Tumorigenesis Mechanisms and Drug Therapy in Neuroblastoma by Mass Spectrometry Based Proteomics.

Ren K, Wang Y, Zhang M, Tao T, Sun Z Children (Basel). 2024; 11(11).

PMID: 39594898 PMC: 11593200. DOI: 10.3390/children11111323.


Vitronectin Levels in the Plasma of Neuroblastoma Patients and Culture Media of 3D Models: A Prognostic Circulating Biomarker?.

Lopez-Carrasco A, Vieco-Marti I, Granados-Aparici S, Acevedo-Leon D, Estan-Capell N, Portugal R Int J Mol Sci. 2024; 25(16).

PMID: 39201421 PMC: 11354570. DOI: 10.3390/ijms25168733.


A comprehensive overview of liquid biopsy applications in pediatric solid tumors.

Janssen F, Lak N, Janda C, Kester L, Meister M, Merks J NPJ Precis Oncol. 2024; 8(1):172.

PMID: 39097671 PMC: 11297996. DOI: 10.1038/s41698-024-00657-z.


Spatial intra-tumour heterogeneity and treatment-induced genomic evolution in oesophageal adenocarcinoma: implications for prognosis and therapy.

Brosda S, Aoude L, Bonazzi V, Patel K, Lonie J, Belle C Genome Med. 2024; 16(1):90.

PMID: 39020404 PMC: 11253399. DOI: 10.1186/s13073-024-01362-z.


References
1.
Su W, Alaminos M, Mora J, Cheung N, La Quaglia M, Gerald W . Positional gene expression analysis identifies 12q overexpression and amplification in a subset of neuroblastomas. Cancer Genet Cytogenet. 2004; 154(2):131-7. DOI: 10.1016/j.cancergencyto.2004.02.009. View

2.
Arechederra M, Avila M, Berasain C . Liquid biopsy for cancer management: a revolutionary but still limited new tool for precision medicine. Adv Lab Med. 2023; 1(3):20200009. PMC: 10197281. DOI: 10.1515/almed-2020-0009. View

3.
von Stedingk K, Gisselsson D, Bexell D . Multidimensional intratumour heterogeneity in neuroblastoma. Oncotarget. 2019; 10(1):3-5. PMC: 6343759. DOI: 10.18632/oncotarget.26524. View

4.
Burgos-Panadero R, Noguera I, Canete A, Navarro S, Noguera R . Vitronectin as a molecular player of the tumor microenvironment in neuroblastoma. BMC Cancer. 2019; 19(1):479. PMC: 6532218. DOI: 10.1186/s12885-019-5693-2. View

5.
Stallings R, Howard J, Dunlop A, Mullarkey M, McDermott M, Breatnach F . Are gains of chromosomal regions 7q and 11p important abnormalities in neuroblastoma?. Cancer Genet Cytogenet. 2003; 140(2):133-7. DOI: 10.1016/s0165-4608(02)00681-7. View